



**THE FOUNDATION
FOR SECURE
MARKETS®**

#54460

Date: April 12, 2024

Subject: Adjusted Q32 Bio Inc. - Cash In Lieu Settlement
Adjusted Option Symbol: QTTB1

Adjusted Q32 Bio Inc. (formerly Homology Medicines, Inc.) options were adjusted on March 26, 2024 (See OCC Information Memo #54354). The new deliverable became 1) 5 Q32 Bio Inc. (QTTB) Common Shares and 2) Cash in lieu of approximately 0.5556 fractional QTTB Shares. Only settlement of the cash portion of QTTB1 options exercise/assignment activity was subject to delayed settlement.

OCC has been informed that a price of \$16.74 per whole QTTB share will be used to determine the cash in lieu amount at a rate of 0.5556. Accordingly, the cash in lieu amount is:

$$0.5556 \times \$16.74 = \$9.30 \text{ per QTTB1 Contract}$$

Now that the exact cash in lieu amount has been determined, OCC will require Put exercisers and Call assignees, during the period of March 26, 2024 through April 12, 2024, to deliver the appropriate cash amount.

The cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

Terms of the QTTB1 options are as follows:

New Deliverable

Per Contract: 1) 5 Q32 Bio Inc. (QTTB) Common Shares
2) \$9.30 Cash

Strike Prices: Unchanged

CUSIP: QTTB: 746964105

Multiplier: 100 (i.e., a premium of 1.50 yields \$150)

Settlement

The QTTB component of QTTB1 exercise/assignment activity from March 26, 2024 through April 11, 2024, has settled through National Security Clearing Corporation (NSCC). The \$9.30 cash amount will be settled by OCC.

Pricing

The underlying price for QTTB1 will be determined as follows:

$$\text{QTTB1} = 0.05 (\text{QTTB}) + 0.0930$$

For example, if QTTB closes at 23.81, the QTTB1 price would be calculated as follows:

$$\text{QTTB1} = 0.05 (23.81) + 0.0930 = 1.28$$

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.